Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Hepatitis C virus (HCV) seems to be the main causative agent of the parenterally transmitted non-A, non-B hepatitis and the detection of anti-HCV may be a marker of ongoing infection with this virus. This study was undertaken to determine the frequency of anti-HCV in 51 haemodialysis patients of our renal unit. In addition association of these antibodies to sex, history of blood transfusions, and duration on haemodialysis, as well as to serological markers of hepatitis B virus infection, was applied. Enzyme-linked immunosorbent assay (ELISA), were used for the detection of all serological markers. Nine of the 51 (17.6%) haemodialysis patients had anti-HCV. The presence of anti-HCV was related to male sex. Although seropositive patients were transfused more often than seronegatives, this difference is not statistically significant. The presence of anti-HCV was associated with the duration of haemodialysis. The majority of anti-HCV patients had serological markers of previous HBV infection, in contrast to seronegative patients.
Nephrol Dial Transplant 1991
PMID:Antibodies against hepatitis C virus (anti-HCV) in haemodialysis patients: association with hepatitis B serological markers. 171 91

Prospective studies have shown that the annual incidence of non-A, non-B (NANB) hepatitis may be high in haemodialysis patients. To assess whether hepatitis C virus (HCV), the major causative agent of post-transfusion and community-acquired NANB hepatitis, has a role in the pathogenesis of liver disease in dialysed patients, we have studied the prevalence and significance of antibodies to HCV in a cohort of patients with end-stage renal disease on chronic haemodialysis treatment. Seventy-four (30%) had circulating antibodies to HCV. Statistically significant associations with the anti-HCV carrier status were duration of haemodialysis treatment, blood transfusions, and the finding of abnormally elevated ALT on retrospective analysis. In contrast, only one of 103 dialysis staff members showed transient positivity for anti-HCV, suggesting a low risk of professional exposure to HCV. These findings suggests that HCV infection is relatively frequent in haemodialysis patients and may be responsible for a significant proportion of liver disease in this clinical setting.
Nephrol Dial Transplant 1991
PMID:Abnormal alanine aminotransferase activity reflects exposure to hepatitis C virus in haemodialysis patients. 171 92

This study reports clinical, serological and immunomorphological observations on viral hepatitis in 14 HBsAg-positive renal transplanted patients treated with cyclosporin and steroids. Eleven patients who were HBsAg positive before transplantation developed signs of hepatitis. This was due to HBV in six cases and progressed into a mild chronic disease. The remaining five subjects lacked signs of HBV reactivation. The hepatitis, attributed to non-A non-B agents, recovered completely. Two more patients became HBsAg positive after transplantation both developed acute hepatitis, respectively drug and HBV related. Transition into chronicity occurred only in the latter case. The results seem to indicate: (1) the possibility of a high incidence of non-B virus hepatitis in HBsAg-positive transplanted patients under cyclosporin treatment; (2) a good prognosis in non-B hepatitis as compared to hepatitis B for the same patient group; and (3) a mild degree of disease activity in cases who develop chronic hepatitis.
Nephrol Dial Transplant 1990
PMID:Viral hepatitis in HBsAg-positive renal transplant patients treated with cyclosporin and steroids. 213 Mar

The incidence of hepatitis B infection among renal transplant recipients was reviewed. Among 90 patients, 13 were HBsAg positive prior to renal transplantation. Episodes of hepatic dysfunction were seen in eight and one died of fulminating hepatitis and disseminated tuberculosis. Silymarin, a herbal extract, appears to confer some benefits in ameliorating hepatic dysfunction. Antibodies to the delta agent were not detected during any of these episodes. One patient contracted hepatitis B after transplantation and rapid reduction in steroid dose was associated with deterioration of liver function. He developed antibodies and cleared the virus. Four HBsAg-negative patients received kidneys from HBsAg positive donors without becoming HBsAg positive.
Nephrol Dial Transplant 1989
PMID:Hepatitis B infection and renal transplantation: the absence of anti-delta antibodies and the possible beneficial effect of silymarin during acute episodes of hepatic dysfunction. 250 38

This paper summarises the information given on the 1985 EDTA Registry centre questionnaire which was returned by 82% of 1959 known dialysis and transplant units in 33 European countries. Trends in the use of different forms of renal replacement therapy are discussed, and attention drawn to the discrepancy between the EDTA centre and individual patient questionnaires as a source of demographic information on dialysis and transplantation. The results of special questions on dialyser re-use, dialysis equipment, AIDS, and hepatitis are presented, and information obtained from the special paediatric section of the centre questionnaire is also given.
Nephrol Dial Transplant 1987
PMID:EDTA Registry Centre Survey, 1985. Report from the European Dialysis and Transplant Association Registry. 312 48

We report three cases of nodular regenerative hyperplasia of the liver: the clinical onset of hepatic disease occurred between 24 and 30 months after renal transplantation. Nodular regenerative hyperplasia was associated with peliosis hepatitis in two cases, and with veno-occlusive disease in one case. Two patients developed portal hypertension, but are doing well. The third patient developed jaundice and died of septic shock. We discuss the aetiological role of renal transplantation, cytomegalovirus infection, and azathioprine in the development of nodular regenerative hyperplasia of the liver.
Nephrol Dial Transplant 1988
PMID:Three cases of nodular regenerative hyperplasia of the liver following renal transplantation. 314 Jan 8

We reviewed the medical records of 177 patients who at 31 December 1985 had been on dialysis treatment for at least one year. Fifty cases of non-A, non-B hepatitis were found: 33 in 70 patients dialysed at the centre and 17 in 107 outpatients (P less than 0.0001). The difference was not related to blood transfusions but to the high prevalence of non-A, non-B in hospital patients who had not been transfused. The time on dialysis before the onset of non-A, non-B hepatitis became gradually shorter, from an average of 82 months before 1980 to 5.7 months in the patients starting haemodialysis after 1983. At follow-up, 7% of patients had abnormal hepatic enzymes 5 years from the onset of acute illness. The epidemiology of non-A, non-B hepatitis in haemodialysis patients appears to be similar to that of hepatitis B. Apart from blood transfusions, contamination of hospital environmental surfaces seems to be the major route of transmission. Our results strongly support a preventive programme for non-A, non-B hepatitis similar to that for hepatitis B, and a separate section for any patient with suspected non-A, non-B hepatitis must be considered.
Nephrol Dial Transplant 1988
PMID:Outbreak of non-A, non-B hepatitis in centre haemodialysis patients: a retrospective analysis. 314 22

With the advances that have occurred over the last two decades in the prevention and treatment of bacterial and fungal infection, viral infection has been recognised as an important problem in renal transplant patients. Four groups of viruses--the herpesviruses, hepatitis viruses, papovaviruses, and adenoviruses - appear to have a particular impact on this patient population, especially the first two of these. The effects of these viruses can be categorised as follows: the production of infectious diseases by the virus itself; the production of an immunosuppressed state that predisposes to opportunistic superinfection; the production of a unique form of allograft injury; and the production of malignancy. It is the recognition of these last three categories of viral effect that has led to a reawakening of interest in these agents in recent years. In particular, the interaction among rejection, innovative forms of immunosuppression, and reactivated viral infection in the pathogenesis of malignant disease, which occurs at a markedly increased rate in this patient population, offers a major frontier of human biology whose importance extends far beyond the renal transplant population.
Proc Eur Dial Transplant Assoc 1983
PMID:Viral infection in the renal transplant patient. 630 2

Over a four year period, 34 patients on chronic haemodialysis with non A-non B hepatitis were studied. Although clinical symptoms were mild or absent in most patients, biochemical evolution seemed to be serious as more than 70 per cent became chronic or showed a relapsing pattern. Blood transfusions play an important role in the spread of this disease; on the other hand in our experience patient to patient transmission was less relevant.
Proc Eur Dial Transplant Assoc 1983
PMID:Incidence, diagnosis and evolution of 'non A-non B' hepatitis in haemodialysis units. 641 25

One hundred and thirty six patients receiving haemodialysis in a HB antigen-free unit were prospectively studied over a period of 29 months for evidence of hepatitis. Twelve/one hundred and eleven patients who were dialysed in this unit for at least one month developed elevation of ALT which proved to be related to neither toxic hepatitis nor hepatitis due to any of the following viruses: hepatitis B virus (HBV), hepatitis A virus (HAV), cytomegalovirus (CMV) or Epstein-Barr virus (EBV). Therefore these cases were considered to be non-A non-B (NANB) hepatitis. In 5 patients the liver disease was of short duration, whereas in 7 others hepatitis had a chronic course with ALT remaining elevated for more than 6 months. During the same period, one/sixty staff members who were working for at least one month in this unit also developed presumed non-A non-B hepatitis. Serological markers of NANB infection tested by double immunodiffusion were present in 10/12 patients and in the one staff member.
Proc Eur Dial Transplant Assoc 1980
PMID:A non-A non-B hepatitis epidemic in a HB antigen-free haemodialysis unit. Demonstration of serological markers of non-A non-B virus. 678 82


<< Previous 1 2 3 4 5 Next >>